DALLAS, March 23, 2021
/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a
clinical stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") platform to transform
oncology drug discovery and development, will present new data on
LP-184, a next-generation, targeted small molecule in the
acylfulvene drug class, showcasing its potency across various 2D
and 3D models of prostate cancer, at the American Association for
Cancer Research (AACR) Virtual Annual Meeting, taking place from
April 10-15, 2021.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
Lantern's poster will highlight the spectrum of DNA damage
repair defects, occurring in 25-30% of metastatic castration
resistant prostate cancer (mCRPC) patients, against which LP-184
shows nanomolar potency. "In vitro studies of LP-184 continue
to show potentially best in class efficacy in metastatic prostate
cancer with a novel mechanism of action," stated Panna Sharma, CEO and President of Lantern
Pharma. "Our ongoing work of LP-184 in metastatic prostate cancer
in collaboration with Georgetown
University has shown effectiveness in tumor models with
mutations in DNA damage repair pathway components including in
genes involved in Homologous Recombination and Transcription
Coupled-Nucleotide Excision Repair. We look forward to sharing this
new data at AACR and developing this compound towards the clinic
and for the benefit of prostate cancer patients."
Details of the abstract are as follows:
Title: LP184, a novel
alkylating agent, is efficacious in prostate cancer models with DNA
damage repair defects
Session Category: Experimental and Molecular
Therapeutics
Session Title: Novel Antitumor Agents
Permanent Abstract Number: 1249
The full text of the abstract is now available on the AACR Annual
Meeting 2021 website.
The accompanying poster will be available to view to registered
participants during the conference via the AACR e-poster website on
April 10, 2021, and published on the
company website after the conference.
Contact
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical
company leveraging advances in genomics, artificial intelligence,
and machine learning by using our proprietary RADR® A.I.
platform to discover biomarker signatures that identify patients
most likely to respond to our pipeline of cancer therapeutics. Our
collaborator-centered business model seeks out industry partners
and leading scientific advisors to capital-efficiently develop our
pipeline of targeted cancer therapeutics. Lantern is currently
developing four drug candidates and an ADC program across seven
disclosed targets, including two phase 2 programs, all focused on
cancers with unique and unmet clinical needs. By targeting drugs to
patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, this approach
represents the potential to deliver best-in-class outcomes. More
information is available at www.lanternpharma.com and Twitter
@lanternpharma.
About LP-184
LP-184 is currently in multiple research
studies in collaboration with leading cancer research institutions.
With the assistance of our RADR® A.I.
platform, LP-184's mechanism of action has been well-characterized
through numerous in-silico and in-vivo studies and
described in published peer-reviewed articles. With observed
nanomolar potency and blood brain barrier permeability, LP-184 is
an alkylating agent that works by causing preferential DNA damage
in certain tumor cells. As shown by CRISPR gene editing techniques,
LP-184 activity is dependent upon the expression of Prostaglandin
Reductase 1 ("PTGR1"), which transforms LP-184 into its bioactive
form by the oxidoreductase activity of PTGR1. Additional
information on LP-184 is available at: Oncology Drug
Development Pipeline - Lantern Pharma.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such
as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements.
There are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of
our collaborators in the area of ATRT may not be
successful; (iii) the risk that we may never receive a
Rare Pediatric Disease Designation for LP-184 in ATRT and may
never qualify for the grant of a Rare Pediatric Disease
Priority Review Voucher (iv) the risk that none of our product
candidates has received FDA marketing approval, and we may not be
able to successfully initiate, conduct, or conclude clinical
testing for or obtain marketing approval for our product
candidates; (v) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (vi)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-present-new-data-supporting-the-advancement-of--lp-184-at-the-aacr-virtual-annual-meeting-2021-301253790.html
SOURCE Lantern Pharma